AA
CBIO

ALPS Advisors’s Crescent Biopharma CBIO Stock Holding History

ALPS Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-788
Closed -$180K – 801
2020
Q1 		$180K Sell
788
-92
-10% -$35.2K ﹤0.01% 781
2019
Q4 		$466K Buy
880
+18
+2% +$9.74K ﹤0.01% 520
2019
Q3 		$371K Sell
862
-42
-5% -$27K ﹤0.01% 543
2019
Q2 		$1.08M Sell
904
-138
-13% -$165K 0.01% 316
2019
Q1 		$1.3M Buy
1,042
+45
+5% +$51.5K 0.01% 275
2018
Q4 		$944K Buy
997
+235
+31% +$283K 0.01% 314
2018
Q3 		$1.1M Buy
762
+145
+24% +$219K 0.01% 364
2018
Q2 		$995K Buy
617
+156
+34% +$268K 0.01% 340
2018
Q1 		$747K Buy
461
+80
+21% +$166K 0.01% 367
2017
Q4 		$639K Buy
+381
New +$504K ﹤0.01% 359

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $718M AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return